GT Biopharma Inc (GTBP)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 09-2025 | 06-2025 | 03-2025 | 12-2024 | 09-2024 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -5,323 | -2,209 | -776 | -13,162 | -9,387 |
| Accounts payable and accrued liabilities | N/A | -1,623 | -1,291 | N/A | N/A |
| Other Working Capital | -2,558 | -1,848 | -1,303 | 828 | -402 |
| Other Operating Activity | -1,012 | 464 | 1,168 | -570 | -647 |
| Operating Cash Flow | $-8,893 | $-5,216 | $-2,202 | $-12,904 | $-10,436 |
| Cash Flows From Investing Activities | |||||
| Change In Deposits | N/A | N/A | N/A | 12,893 | 12,892 |
| Investing Cash Flow | $N/A | $N/A | $N/A | $12,893 | $12,892 |
| Cash Flows From Financing Activities | |||||
| Common Stock Issued | 1,052 | 1,052 | N/A | 2,976 | 2,976 |
| Common Stock Repurchased | N/A | N/A | 616 | N/A | N/A |
| Dividend Paid | -85 | N/A | N/A | N/A | N/A |
| Other Financing Activity | 6,503 | 5,441 | 0 | 0 | 0 |
| Financing Cash Flow | $7,470 | $6,493 | $616 | $2,976 | $2,976 |
| Beginning Cash Position | 4,044 | 4,044 | 4,044 | 1,079 | 1,079 |
| End Cash Position | 2,621 | 5,321 | 2,458 | 4,044 | 6,511 |
| Net Cash Flow | $-1,423 | $1,277 | $-1,586 | $2,965 | $5,432 |
| Free Cash Flow | |||||
| Operating Cash Flow | -8,893 | -5,216 | -2,202 | -12,904 | -10,436 |
| Free Cash Flow | -8,893 | -5,216 | -2,202 | -12,904 | -10,436 |